Thank you! Your submission has been received!
It looks like that email is already in our system - thanks for signing up!
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
×
back to portfolio︁
Excision BioTherapeutics

Excision develops CRISPR-based therapies to cure viral infectious diseases. The company’s first targeted viral infection is HIV, with a pipeline to begin trials on treatments for Herpes Simplex Virus, JC Virus/PML andHepatitis B in the next ~2-3 years.

The Excision approach is the first technology in history to remove HIV genomes from animals and generate a functional cure for HIV.

Exited

MANAGEMENT TEAM

Daniel Dornbusch

INVESTMENT TEAM

Michael Marks

Category

Life Sciences

HQ

San Francisco, Calif.

Related Portfolio